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Non-invasive molecular imaging of
inflammatory macrophages in allograft
rejection
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Jonathan D. Cooper4, Paul R. Crocker5, Wilson Wong3 and Gregory E. D. Mullen1,3
Abstract
Background: Macrophages represent a critical cell type in host defense, development and homeostasis. The ability
to image non-invasively pro-inflammatory macrophage infiltrate into a transplanted organ may provide an additional
tool for the monitoring of the immune response of the recipient against the donor graft. We therefore decided to image
in vivo sialoadhesin (Sn, Siglec 1 or CD169) using anti-Sn mAb (SER-4) directly radiolabelled with 99mTc pertechnetate.
Methods: We used a heterotopic heart transplantation model where allogeneic or syngeneic heart grafts were
transplanted into the abdomen of recipients. In vivo nanosingle-photon emission computed tomography (SPECT/CT)
imaging was performed 7 days post transplantation followed by biodistribution and histology.
Results: In wild-type mice, the majority of 99mTc-SER-4 monoclonal antibody cleared from the blood with a half-life of
167 min and was located predominantly on Sn+ tissues in the spleen, liver and bone marrow. The biodistribution in the
transplantation experiments confirmed data derived from the non-invasive SPECT/CT images, with significantly higher
levels of 99mTc-SER-4 observed in allogeneic grafts (9.4 (±2.7) %ID/g) compared to syngeneic grafts (4.3 (±10.3) %ID/g)
(p = 0.0022) or in mice which received allogeneic grafts injected with 99mTc-IgG isotype control (5.9 (±0.6) %ID/g)
(p = 0.0185). The transplanted heart to blood ratio was also significantly higher in recipients with allogeneic grafts
receiving 99mTc-SER-4 as compared to recipients with syngeneic grafts (p = 0.000004) or recipients with allogeneic
grafts receiving 99mTc-IgG isotype (p = 0.000002).
Conclusions: Here, we demonstrate that imaging of Sn+ macrophages in inflammation may provide an important
additional and non-invasive tool for the monitoring of the pathophysiology of cellular immunity in a transplant model.
Keywords: Macrophages, Cardiac transplantation, Preclinical imaging, Sialoadhesin, SER-4
Background
Macrophages are tissue-resident components of the innate
and adaptive immune systems and perform a variety of
functions in host defense and maintenance of homeostasis
[1]. As such, they are crucial in the progress and resolution
of a variety of pathological conditions, including cancer,
autoimmunity, atherosclerosis and rejection of transplanted
organs [2]. There are a variety of antigens used in the
ex vivo identification of human macrophages, and of these,
the markers CD64, CD68 (Macrosialin), CD163, CD169
(sialoadhesin) and CD204 (macrophage scavenger receptor
A) represent the set of trans-species pan-macrophage
markers [3]. Due to the significant plasticity of macrophage
phenotype, producing a single macrophage marker has
eluded researchers and none is uniquely expressed on mac-
rophages. CD64 is expressed on monocytes and subsets of
germinal and blood dendritic cells, CD68 on various leuko-
cytes, CD163 on monocytes, CD204 on monocytes and
dendritic cells, and of the most myeloid restricted of these
(CD163) significant amounts are found as soluble product
[4], complicating its use for in vivo non-invasive imaging.
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To date, the majority of macrophage imaging has been
performed by magnetic resonance imaging (MRI) using
non-specific nanoparticles such as superparamagnetic iron
oxide (SPIO). SPIOs were injected intravenously (i.v.) and
taken up in vivo by phagocytic cells [5]. This uptake is not
unique to macrophages and cells such as dendritic cells can
also take up iron oxide particles [6]. Other approaches have
involved ex vivo non-specific labelling of macrophages with
a contrast agent, such as a nanoparticle or a radiolabel,
followed by MRI or single-photon emission computed tom-
ography imaging (SPECT) imaging [7]. Recently, the target-
ing of macrophages with labelled antibodies has begun to
be explored, with a number of groups reporting success
with this technology in preclinical models. 111In-labelled
anti-F4/80-A3-1 [8], 68Ga-labelled CD163 [9] and optically
labelled CD206 [10] have shown the feasibility and utility of
macrophage targeting in vivo. In addition, radiotracers
targeting translocator protein (TSPO) as a biomarker of
microglial activation and macrophage infiltration in the
brain have been used [11].
Here, we report non-invasive in vivo imaging specific
for inflammatory macrophages using the anti-sialoadhesin
(Sn, Siglec 1 or CD169) monoclonal antibody, SER-4 [12].
Increasing attention is being paid towards the marker Sn
[13, 14], which under quiescent conditions is expressed on
subsets of macrophages in secondary lymphoid tissues,
such as the lymph nodes and spleen [12]. However, Sn+
macrophages can also be found in a variety of pathological
conditions [15–17]. Sn+ macrophages not only exhibit
classic innate immune cell behaviour by acting as profes-
sional phagocytes but also display a close relation in pro-
moting immune responses [18] through the activation of
other immune effector cells including CD8 T cells [19], B
cells [20] and iNKT cells [21]. This relationship is demon-
strated by enhanced immunity resulting from the targeting
of antigenic material to Sn+ macrophages [22, 23] and also
by the amelioration of autoimmunity following Sn knock-
down [24–26]. Increasingly, Sn expression is being linked
clinically with disease progression in a variety of settings
and is finding use as a marker of inflammation [27].
There is still a clinical necessity for further develop-
ment of non-invasive imaging biomarkers not only for
the diagnosis and staging of disease but also for interim
assessment of therapies. Solid organ transplantation is
one area where the development of a non-invasive im-
aging biomarker would aid therapy response assessment.
The incidence of acute transplant rejection within the
first year has decreased dramatically by the introduction
of modern immunosuppressive therapies, while the rates
of chronic transplant rejection have remained high [28].
While efforts are underway for the non-invasive imaging
of ischemia reperfusion injury post transplantation [29],
not much has been done in the way of non-invasive im-
aging of recipient macrophages in graft rejection. Thus,
close surveillance of transplanted organs remains im-
perative. The current clinical standard of repetitive inva-
sive endomyocardial biopsies is prone to sampling error,
entails a risk of severe complications, causes discomfort
and anxiety for the patients and, unlike for kidney trans-
plants, is usually performed as a last resort. Therefore,
developing non-invasive yet quantitative diagnostic tools
for the monitoring of allograft rejection would fulfil an
unmet clinical need.
The aim of this study is to test the biodistribution
of 99mTc-SER-4 in normal animals and an inflamma-
tory model such as an acute rejection model.
Methods
Mice, culture media, reagents and antibodies
C57BL/6 (H-2b) and BALB/c (H-2d) mice were ordered
from Harlan Olac (Bicester, UK). Sn knockout (Sn-/-) mice
were bred and maintained in the Biological Services Unit
at King’s College London. RPMI 1640 medium (Sigma,
Poole, UK), supplemented with 5 mM L-Glut (Invitrogen,
Paisley, UK), 100 U/mL penicillin (Invitrogen), 100 μg/mL
streptomycin (Invitrogen), 10 % IgG-depleted foetal calf
serum (Source Bioscience UK Ltd., Nottingham, UK),
1 mM Hepes (Invitrogen) and 0.05 mM mercaptoethanol
(Invitrogen), was used for antibody production, labelling
and in vitro binding assays. Antibodies were purified using
5 mL HiTrap Protein G HP and 13.5 mL G-25 Sephadex
desalting columns (PD-10) (GE Healthcare, Chalfont St.
Giles, UK). Size exclusion chromatography (SEC) was
performed using an Agilent 1200 series (Agilent, Oxford,
UK) high-performance liquid chromatography (HPLC)
system with in-line UV (280 nm) and radionuclide
detector (Flow-Count, LabLogic, UK).
Purification and technetium-99 m radiolabeling of SER-4
antibody
Anti-mouse Sn SER-4 antibody was isolated as previ-
ously described using the SER-4 hybridoma [12]. Briefly,
SER-4 hybridoma cells were grown in Celline CL350
(Integra Biosciences AG, Zissers, Switzerland) according
to manufacturer’s instructions. Tissue culture media was
then harvested and purified on a protein G column
followed by dialysis into PBS (Gibco). The SER-4 and
the anti-mouse IgG isotype control (AbD Serotec, Oxon,
UK) antibodies were directly radiolabelled with 99mTc.
Briefly, antibodies were concentrated to 10 mg/mL,
using a Vivaspin 20 centrifugal concentrator (Sartorius
Stedim, Epsom, UK), and 2 mg (200 μL, 13 nM) was
then reduced by a molar excess of 2-mercaptoethanol
(2-ME, 2000:1, 2 μl, 26 μM) at room temperature for
30 min. The reduced antibody was purified using a PD-10
desalting column and stored in PBS at −80 °C at 5 mg/mL.
For antibody radiolabeling, 5 μl of a reconstituted MDP kit
(Medronate Draximage, Draxis, USA) was added to 0.1 mg
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(20 μL, 0.67 nM) of reduced SER-4, followed by the
addition of 150 MBq of sodium pertechnetate (provided by
Department of Nuclear Medicine at Guys Hospital, UK).
Labelling efficiency was measured using instant thin layer
chromatography strips (ITLC-SA) (Varian Medical Systems
UK, Ltd., Crawley, UK) with a mobile phase of 0.1 M cit-
rate buffer, pH 5 and analysed using a gamma ray TLC
scanner (Lablogic, UK). The amount of colloids has not
been assessed but that large colloids anyway would have
been eliminated by filtration prior to injection.
Stability assay
Fifty MBq of 99mTc SER-4 was added to AB type hu-
man serum (Sigma) or PBS at 1:4 v/v and incubated at
37 °C for 20 h. Samples were analysed at 0, 3, 6 and
20 h by HPLC-SEC using a BioSep SEC-300 column
(Phenomenex, Macclesfield, UK) with an isocratic mo-
bile phase of 100 mM phosphate buffer pH 7.0 at a
flow rate of 1 mL/min. Stability was calculated as the area
under the 99mTc-SER-4 peak (retention time = 8 min and
30 s) versus the area under the curve of the unbound 99mTc
peak (retention time = 18 min).
In vitro 99mTc SER-4 binding assay
Of labelled antibody, 0.1 μg was added to 0.2 μg of re-
combinant Sn-Fc fusion protein (Sn-Fc, 6.7 μg/ml) and
incubated at 37 °C for 10 min. The proteins were filtered
through a 0.2-μm syringe filter and binding to Sn-Fc was
measured by HPLC-SEC and compared to the 99mTc-
IgG isotype binding. Specificity was shown in blocking
studies using a 10-fold excess of cold SER-4. No Kd or
immunoreactive fraction measurements were performed;
as the authors felt that the in vitro competitive binding
assay was sufficient to proceed to preclinical studies.
NanoSPECT/CT transplant imaging
Heterotopic cardiac transplantations were performed on
8- to 10-week-old male C57BL/6 mice (three groups, n = 5
for SER4 allogeneic and isotype allogeneic groups) with
heart graft from BALB/c mice while syngeneic cardiac
transplants (n = 4 for SER4 syngeneic group) with heart
grafts from C57BL/6 mice as described by Corry et al [30].
All mice were imaged and ex vivo biodistribution was per-
formed. Briefly, superior and inferior vena cava and pul-
monary veins of the heart graft were ligated. The donor
aorta was then anastomosed to the recipient abdominal
aorta and the donor pulmonary artery anastomosed to the
inferior vena cava, resulting in a fully vascularised hetero-
topic transplant. C57BL/6, Sn-deficient (Sn-/-) and trans-
planted mice were anesthetized with inhaled isoflurane
gas (VetOne, UK) and ~10 μg (~20 MBq) of 99mTc-
SER-4 or 99mTc-IgG isotype control was filtered through
a 0.2-μm syringe filter and administered intravenously.
Single-photon emission computed tomography (SPECT)
images were obtained 3 h post injection using a nanoS-
PECT/computed tomography (CT) preclinical scanner
(Bioscan Inc., Washington, DC, USA) equipped with four
heads, each with 1-mm multipinhole collimator, in helical
scanning mode in 24 projections over 30 min. The CT im-
ages were obtained with 45 kVP X-ray source, 1000 ms ex-
posure time in 180 projections over 10 min. Images were
Fig. 1 99mTc-SER-4 binds to Sn. Binding studies were performed by
incubating 99mTc-SER-4 and Sn-Fc followed by analysis with radio-HPLC
size exclusion chromatography. a 99mTc-SER-4 elutes at 8 min and 35 s.
b 99mTc-SER-4 was added to Sn-Fc and an elution peak at 7 min and
20 s was observed corresponding to the 99mTc-SER-4 bound to Sn-Fc.
c When 99mTc-SER-4 was added to Sn-Fc protein in the presence of
unlabelled SER-4, no binding was observed and only the 99mTc-SER-4
elution peak was observed. d 99mTc-IgG isotype control did not bind to
Sn-Fc with a peak elution time similar to 99mTc-SER-4 of 8 min and 35 s
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reconstructed in a 256 by 256 matrix using the HiSPECT
(Scivis GmBH) reconstruction software package and fused
using InVivoScope software (Bioscan). Images shown here
are maximum intensity projections (MIP). Animals were
then euthanized at 4 h post injection and tissues explanted,
weighed and gamma counted on a gamma counter (Wallac,
1282 Compugamma, PerkinElmer, UK). Uptake in each
tissue was expressed as percent injected dose per gram of
tissue (%ID/g). The transplanted heart to blood ratio was
calculated by expressing the %ID/g of the transplanted
heart divided by %ID/g in the blood. After imaging, C57BL/
6 wild-type and Sn-/- spleens or grafted hearts and spleens
from C57BL/6 recipients were removed for histology which
was performed as previously described [12].
Immunostaining
After imaging and biodistribution, frozen tissues were stained
for Sn using SER-4 followed by anti-rat-biotin then streptavidin-
HRP. Sn+ macrophages were visualized with Vector NovaRED
substrate (red) and sections counterstained with haemotoxylin.
Statistical analysis
To test for a significant differences between 99mTc-SER-4
in allogeneic and syngeneic transplants with 99mTc-IgG in
Fig. 2 99mTc-SER-4 NanoSPECT/CT imaging and biodistribution of Sn+ macrophages. C57Bl/6 wild-type (WT) mice were imaged a 0.5 h, b 1 h, c
3 h and d 6 h post injection with 99mTc-SER-4. Arrows indicate uptake of tracer by Sn+ macrophages in the spleen (S), liver (L) and bone marrow
(BM). After imaging, C57BL/6 wild-type (WT) mice were euthanized and tissues explanted, weighed and gamma counted. Maximum intensity
projections are shown. e 99mTc-SER-4 biodistributions at 1, 3 and 6 h post injection were expressed as percentage injected dose per gram of
tissue (%ID/g). Error bars represent the standard error of the mean of n = 3
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allogeneic heart transplants, a one-way ANOVA was first
performed; p values of <0.05 were considered significant.
If the one-way ANOVA was significant, then a post hoc
analysis was performed with Student–Newman–Keuls
pairwise comparison; p values of <0.05 were considered
significant.
Results
99mTc-SER-4 is stable in serum and binds to sialoadhesin
Anti-Sn antibody was produced using the SER-4 hybrid-
oma. SER-4 antibody was reduced with mercaptoethanol
and directly radiolabelled with sodium pertechnetate in
the presence of methylene-diphosphonate ligand. The
radiolabelling efficiency as measured by ITLC was >99 %
with a specific activity of 1.5 MBq/μg of antibody. 99mTc-
SER-4 remained stable in serum for 20 h with only one
radioactive peak observed at a retention time of 8 min
(see Additional file 1). However, when either the 99mTc-
SER-4 or 99mTc-IgG was incubated in PBS alone, free per-
technetate was observed after 20 h (see Additional file 1).
To ensure that the radiolabelling procedure did not
adversely affect the ability of SER-4 to bind to Sn, an in
vitro binding assay was developed. Binding was deter-
mined by observing a shift in retention time from 8 min
and 35 s of unbound 99mTc-SER-4 (Fig. 1a) to 99mTc-
SER-4 bound to Sn-Fc with a retention time of 7 min
and 20 s (Fig. 1b). The binding of 99mTc-SER-4 bound to
Sn-Fc was inhibited by the addition of unlabelled SER-4
antibody (Fig. 1c). The 99mTc-IgG isotype control did
not bind to Sn-Fc and eluted with a retention time of
8 min and 30 s similar to that of unbound 99mTc-SER-4
(Fig. 1d).
Fig. 3 99mTc-IgG and 99mTc-SER-4 nanoSPECT/CT imaging and biodistribution in C57Bl/6 wild-type (WT) and Sn-/- (KO) mice. Imaging was
performed 3 h post injection on C57Bl/6 WT mice with a 99mTc-IgG isotype control or b 99mTc-SER-4 or c Sn-/- mice with 99mTc-SER-4. Arrows
indicate signal arising from carotid arteries (CA), heart (H), aorta (A) and bladder (B). Maximum intensity projections are shown. d Biodistribution
of 99mTc-SER-4 in C57Bl/6 wild-type, Sn-/- and 99mTc-IgG isotype control in C57Bl/6 wild-type mice were expressed as percentage injected dose
per gram of tissue (%ID/g). Error bars represent the standard error of the mean of n = 5
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We did not run an SDS-PAGE to show that the anti-
body remains intact as the radiolabeled antibody is still
able to bind >99 % to Sn antigen which is completely
blocked by cold antigen in a competitive binding assay.
Biodistribution of 99mTc-SER-4 in mice
C57BL/6 wild-type mice, injected with 20 MBq of 99mTc-
SER-4, were imaged at 0.5, 1, 3 and 6 h post injection
(Fig. 2). At 1 h, 99mTc-SER-4 uptake was already observed
in the spleen, liver and bone marrow, which were the ex-
pected locations of Sn+ macrophages. Additionally, bladder
uptake is consistent with previous studies of directly la-
belled antibodies and is thought to result from transchela-
tion of 99mTc from disulphides to endogenous cysteine
[31]. It has been previously shown that antibodies labelled
via the direct labelling method which were then challenged
with cysteine led to ~10 % translocation of the Tc-99 m to
the cysteine [32].
Blood levels of 99mTc-SER-4 continued to drop
between 3 and 6 h. After imaging, mice were euthanized
and standard radioactive biodistribution was performed.
The biodistribution results confirmed the non-invasive
SPECT/CT images (Fig. 2e). 99mTc-SER-4 clears the
blood rapidly with 66.7 %ID/g in the blood immediately
post injection to 15.0 ± 0.9 %ID/g at 6 h with a clearance
half-life in blood of 167 min (p = 0.0004). This is signifi-
cantly faster blood clearance than expected for most
radiolabelled monoclonal antibodies.
As a control, 99mTc-SER-4 or 99mTc-IgG isotype was
injected into Sn-/- or C57BL/6 wild-type mice, respectively,
and imaged by nanoSPECT/CTat 3 h post injection (Fig. 3).
Both 99mTc-SER-4 and 99mTc-IgG remained in the blood of
Sn-/- or wild-type mice, respectively, and reflected the typ-
ical biodistribution expected of a 150-kDa radiolabelled
monoclonal antibody. Biodistribution results confirmed the
SPECT/CT images where the majority of the 99mTc-SER-4
(200 ± 66.0 %ID/g) was observed in the spleen of wild-type
mice. Splenic uptake was lower for 99mTc-SER-4 (8.3 ±
1.1 %ID/g) or 99mTc-IgG (16.5 ± 2.6 %ID/g) in Sn-/- or wild-
type mice, respectively (p = 0.0029 and 0.0025, respectively).
The majority of 99mTc-IgG (52.9 ± 7.0 %ID/g) in
wild-type mice was retained in the blood as com-
pared to 99mTc-SER-4 in wild-type mice (26.1 ±
5.4 %ID/g) (Fig. 3d) (p = 0.002). Staining of spleen
sections from wild-type mice with SER-4 gave the
distinctive stain of Sn+ marginal metallophilic mac-
rophages (MMM) in the internal border of the white
pulp (Additional file 2). Raw biodistribution data for
blood clearance and controls are available in supple-
mental data (Additional files 3 and 4).
Non-invasive imaging of 99mTc-SER-4 targets Sn+
macrophages in heterotopic cardiac transplantations
Seven days after transplantation of allogeneic or syngeneic
heart grafts into the abdomen, recipients underwent nanoS-
PECT/CT imaging at 3 h post injection of 99mTc-SER-4
(Fig. 4). Uptake was observed in the allogeneic graft in the
abdomen of recipients (Fig. 4a) but not in recipients receiv-
ing a syngeneic graft (Fig. 4b). Again, high levels of 99mTc-
SER-4 were observed in the spleen, liver and bone marrow
with only low levels of uptake in non-target tissues.
A B E D C 
F G H 
Fig. 4 99mTc-SER-4 nanoSPECT/CT imaging of Sn+ macrophages in heterotopic cardiac transplant model. Representative maximum intensity
projection nanoSPECT/CT images of recipients with either a allogeneic or b syngeneic heart graft imaged 3 h post injection with 99mTc-SER-4. CT,
SPECT and fused images from coronal (c, d, e, respectively) and transversal (f, g, h, respectively) planes are also shown. Arrows indicate site of
abdominal cardiac transplant with uptake of tracer in allogeneic heart graft that are absent in the syngeneic heart graft model
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Biodistribution data confirmed a significantly higher
uptake of 99mTc-SER-4 in the allogeneic heart grafts
(9.4 ± 2.7 %ID/g) compared to syngeneic heart graft
(4.3.0 ± 0.3 %ID/g) (p = 0.0022) or in mice which re-
ceived allogeneic grafts and injected with 99mTc-IgG
isotype control (5.9 ± 0.6 % ID/g) (p = 0.0185) (Fig. 4).
Given that 50.3 ± 2.2 %ID/g of the 99mTc-IgG isotype
control was observed at 4 h in the blood, transplanted
heart to blood ratios were also calculated. The heart to
blood ratio was significantly higher in recipients with
allogeneic grafts receiving 99mTc-SER-4 as compared to
recipients with syngeneic grafts (p = 0.000004) or recip-
ients with allogeneic grafts receiving 99mTc-IgG isotype
(p = 0.000002) (Fig. 5). Raw biodistribution data for
transplanted mice is available in supplemental data
(Additional file 5).
The presence of Sn+ macrophages in allogeneic grafts
was confirmed in transplants stained with anti-Sn.
Allogeneic grafts showed an abundance of Sn+ macro-
phages while sporadic expression of Sn+ macrophages
were observed in syngeneic grafts and minor staining in
recipient’s native hearts (Fig. 6).
Discussion
We have been able to perform non-invasive imaging
specific for macrophages using a radiolabelled anti-
body. Although much is known about the phenotype
of macrophages, these have not been exploited for the
development of non-invasive imaging contrast agents.
Monoclonal antibodies are being successfully used in
immunotherapy of diseases such as cancer where they tar-
get antigens such as HER2 using trastuzumab (Herceptin),
EGFR with panitumumab (Vectibix) and VEGF-A with
bevacizumab (Avastin). Antibodies targeted specifically at
immune cells, such as granulocytes, B and T cells, have
also been evaluated as diagnostic contrast agents for the
Fig. 5 Biodistribution of 99mTc-SER-4 in heterotopic cardiac transplant model. a Biodistribution of 99mTc-SER-4 in recipients of allogeneic heart graft,
syngeneic heart grafts or allogeneic heart grafts at 4 h post injection of 99mTc-IgG isotype control. b Transplanted heart to blood ratios for 99mTc-SER-4
in recipients of allogeneic heart graft, syngeneic heart grafts or allogeneic heart grafts injected with 99mTc-IgG isotype control. Error bars represent the
standard error of the mean of n = 4–5
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imaging of infection, rheumatoid arthritis and transplant
rejection [33]. However, to date, few antibodies are used
routinely for diagnostic imaging and many of these have
been withdrawn from the market or are still under clinical
development [34].
With macrophages being implicated, for better or worse,
in many diseases, it is important to be able to target these
cells non-invasively to assess prognosis as well as interim
assessment of therapeutic interventions. We therefore de-
cided to radiolabel one of the most restricted macrophage
surface markers sialoadhesin (CD169). Low expression of
Sn was observed in many tissue macrophages (such as in
the liver, dermis and lung) but significant expression was
observed in macrophages in the secondary lymphoid
organs and bone marrow [12]. Sn expression can be
upregulated in inflammation via inflammatory mediators
such as TNF-α and type I IFN in humans, rats and pigs
[15, 35, 36]. SER-4 was radiolabelled with the radioiso-
tope 99mTc(99mTc-SER-4) and found to be stable in
serum but lower stability was observed in PBS after 20 h.
We then performed in vivo imaging and biodistribution
studies in wild-type mice and in a murine model of hetero-
topic cardiac transplant. The majority of 99mTc-SER-4
monoclonal antibodies was cleared from the blood within
3 h and was located in predominately Sn+ M tissues such
as the spleen, liver and bone marrow. 99mTc-SER-4 uptake
was not observed in these tissues in Sn-/- mice, and 99mTc-
IgG isotype control remained in the blood for the duration
of the experiment. In the heterotopic cardiac transplants, it
was possible to observe 99mTc-SER-4 in allogeneic heart
grafts but not in syngeneic heart grafts. This was further
quantified by the biodistribution studies which showed
significant uptake of 99mTc-SER-4 as compared to radi-
olabelled isotype control or syngeneic. Histology of the
transplanted grafts also demonstrated the presence of
Sn+ macrophages in the allogeneic heart grafts, and
only sporadic expression was observed in the syngeneic
or native hearts.
Conventional wisdom tells us that monoclonal anti-
bodies are too large for fast real-time in vivo imaging as
they take several days to clear from the blood and also
penetrate tissue slowly. However, if one is able to clear
non-targeted radiolabelled antibodies quickly from circula-
tion by either providing a fast excretion route via the kidney
or liver (which is unlikely for large antibodies) or an
endogenous “sink” (identified by biodistribution to be pre-
dominantly bone marrow, liver and spleen), then significant
targeting of regions of interests may be possible even with
low target to background ratios. We have previously also
seen evidence of this sink when using antibodies targeting
macrophages at 24 h post injection [8]. To note, we did see
non-specific uptake in the kidney using 99mTc-SER-4 bio-
distribution data which may question its suitability for
imaging macrophage infiltration in kidney transplants.
More recent studies have indicated a role for
macrophage-mediated rejection as a contributing factor
for the progressive decline in graft function, indicating
that current immunosuppressive treatment protocols fail
to keep at bay the potent effector responses of the adap-
tive immune system [37]. This imaging technique could
equally be used in imaging a model of chronic rejection,
and as with acute rejection, the current view is that
macrophages promote worse graft outcome through the
release of inflammatory mediators and regulation of the
cytokine dynamics [38]. Macrophages are a major com-
ponent of inflammatory infiltrates in rejecting allografts
[39]. Macrophages are rapidly recruited to sites of
inflammation including allografts where they are respon-
sive to type I interferons, while at the same time potent
producers of pro-inflammatory cytokines such as IL-1,
IL-6 and TNF-beta [40]. The early infiltration of macro-
phages post organ transplantation has been observed in
biopsies demonstrating acute cellular rejection as well as
in acute humoral rejection and has been shown to be
associated with relatively poor allograft survival [41].
More recently, increased monocyte expression of sia-
loadhesin was observed during acute cellular rejection
after intestine transplantation in children [42].
Conclusions
Radiolabelled SER4 has demonstrated the ability to spe-
cifically image non-invasively pro-inflammatory macro-
phage infiltrate into rejected grafts, which may provide
an important additional tool for the monitoring of
transplanted organs.
A B 
C D 
Allogeneic Syngeneic 
C
ar
di
ac
 T
ra
ns
pl
an
t 
N
at
iv
e 
H
ea
rt
 
Fig. 6 Cardiac histology. Histology of heterotopic cardiac sections
from a allogeneic grafts and b syngeneic grafts are shown. Controls
were performed by staining of both c allogeneic and d syngeneic
recipient heart tissue. Images are shown at ×20 magnification
(scale bar = 100 μm)
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Additional files
Additional file 1: Figure S1. Serum stability of 99mTc-SER-4. 99mTc-SER-4
was incubated in the presence of phosphate-buffered saline (B) or serum
(C) for 20 h at 37 °C then injected into SEC radioHPLC system. Percentage
bound was assessed by comparison of bound activity (integral of 8 min
and 25 s peak) to that of free activity (integral of 17 min and 45 s peak).
99mTcO4 is included as a control (A). (PDF 73 kb)
Additional file 2: Figure S2. Spleen sections from wild-type animals
stained with SER-4 and counterstained with haematoxylin. White arrow
denotes white pulp, black arrow denotes red pulp and black arrowhead
denotes marginal metallophilic macrophages. (PDF 798 kb)
Additional file 3: Table S1. Timecourse biodistribution of 99mTc-SER-4
in wild-type mice. Biodistribution of 99mTc-SER-4 in wild-type mice at 1, 3
and 6 h post injection. Data expressed as percentage injected dose per
gram of tissue (%ID/g). (PDF 63 kb)
Additional file 4: Table S2. Biodistribution of 99mTc-IgG and 99mTc-SER-4
in C57Bl/6 wild-type (WT) and Sn-/- (KO) mice. Biodistribution of 99mTc-IgG
isotype control in C57Bl/6 wild-type mice (WT × Isotype) 99mTc-SER-4 in
C57Bl/6 wild-type (WT × 99mTc-SER4) and Sn-/- mice (Sn KO × 99mTcSER4)
were expressed as percentage injected dose per gram of tissue (%ID/g).
(PDF 70 kb)
Additional file 5: Table S3. Biodistribution of 99mTc-SER-4 in heterotopic
cardiac transplant model. Biodistribution of 99mTc-SER-4 in recipients of
allogeneic heart graft (mouse 1–5), syngeneic heart grafts (mouse 6–9),
or allogeneic heart grafts at 4 h post injection of 99mTc-IgG isotype
control (mouse 10–14). Data expressed as percentage injected dose per
gram of tissue (%ID/g). (PDF 67 kb)
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